After peaking in 2024, venture investments in startups involved in the space declined last year. But a broader adoption of AI ...

In an interview with Stephen Onikoro, chief operating officer of PharmaForceIQ, he shared that pharma marketers can’t pour ...

Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after ...

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for ...

Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.

Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock ...

Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.

At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning ...

Though its data could be useful for pharmaceutical firms, Polansky’s latest entrepreneurial endeavor, Outer Bio, is serious ...

The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A ...

A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in ...

Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated ...